Egalet Appoints Jeffrey M. Dayno, M.D. as Chief Medical Officer
July 28, 2014 08:30 ET
|
Egalet Corporation
WAYNE, Pa., July 28, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the appointment of Jeffrey M. Dayno, M.D. as chief medical officer (CMO). Dr. Dayno will be...
Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical and Chemical Manipulation
July 15, 2014 08:30 ET
|
Egalet Corporation
WAYNE, Pa., July 15, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced positive results from the Category 1 abuse deterrence study for Egalet-001, an...
Egalet to Present at Upcoming Investor Conferences in June
May 22, 2014 08:00 ET
|
Egalet Corporation
WAYNE, Pa., May 22, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present at multiple...
Egalet to Present at the 13th Annual Needham Healthcare Conference on April 9
April 02, 2014 08:00 ET
|
Egalet Corporation
WAYNE, Pa., April 2, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present next week at...
Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes
April 01, 2014 08:00 ET
|
Egalet Corporation
WAYNE, Pa., April 1, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet"), a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral...
Egalet Reports Positive Outcome of First Phase of Category 1 Abuse Deterrence Studies for Egalet-001
March 31, 2014 08:00 ET
|
Egalet Corporation
WAYNE, Pa., March 31, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced positive results of the first phase of the category 1 abuse deterrence studies for...
Egalet Initiates Bioequivalence Studies for Abuse-Deterrent Morphine Egalet-001
March 25, 2014 08:00 ET
|
Egalet Corporation
WAYNE, Penn., March 25, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the initiation of the bioequivalence (BE) program for Egalet-001, an abuse-deterrent,...
Egalet Appoints Timothy P. Walbert to Board of Directors
March 11, 2014 08:00 ET
|
Egalet Corporation
WAYNE, Pa., March 11, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of...
Egalet IPO Underwriters Exercise Over-Allotment Option
March 10, 2014 08:00 ET
|
Egalet Corporation
WAYNE, Pa., March 10, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that the underwriters of its initial public offering (IPO) have exercised their option to...
Egalet Enters Into Development Collaboration and License Agreement With Shionogi Limited for Abuse-Deterrent Oral Hydrocodone Opioid Product Candidates
November 26, 2013 08:00 ET
|
Egalet Corporation
MALVERN, Pa., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Egalet Corporation ("Egalet") announced today that it has entered into a definitive collaboration and license agreement with Shionogi Limited...